中国临床药学杂志

参考文献

[1]RODRíGUEZ MURúA S,FAREZ M F,QUINTANA F J.The immune response in multiple sclerosis[J].Annu Rev Pathol,2022,17:121.

[2]MS International Federation.Atlas of MS 2020-Epidemiology report[EB/OL].[2023-06-25].https://www.msif.org/resource/atlas-of-ms-2020/.

[3]DOBSON R,GIOVANNONI G.Multiple sclerosis-a review[J].Euro J Neurology,2019,26(1):27.

[4]OH J,VIDAL-JORDANA A,MONTALBAN X.Multiple sclerosis:clinical aspects[J].Curr Opin Neurol,2018,31(6):752.

[5]邱伟,徐雁.多发性硬化诊断和治疗中国专家共识(2018版)[J].中国神经免疫学和神经病学杂志,2018,25(6):387.

[6]MONTALBAN X,GOLD R, THOMPSON A J,et al.ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis[J].Mult Scler,2018,24(2):96.

[7]YAMOUT B,ALROUGHANI R,AL-JUMAH M,et al.Consensus guidelines for the diagnosis and treatment of multiple sclerosis[J].Curr Med Res Opin,2013,29(6):611.

[8]CROSS A,RILEY C.Treatment of multiple sclerosis[J].CONTINUUM,2022,28:1025.

[9]HABEK M,AD AMEC I,BARUN B,et al.Treatment of relapsing multiple sclerosis-recommendations of the Croatian Neurological Society[J].Croat Med J,2022,63(4):379.

[10]HRNCIAROVA T,DRAHOTA J,SPELMAN T,et al.Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy?A comparison of patients with relapsingremitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries[J].Mult Scler Relat Disord,2023,76:104803.

[11]ONTANEDA D,TALLANTYRE E,KALINCIK T,et al.Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis[J].Lancet Neurol,2019,18(10):973.

[12]ENGLISH C, ALOI J J.New FDA-approved disease-modifying therapies for multiple sclerosis[J].Clin Ther,2015,37(4):691.

[13]GROSS R H,CORBOY J R.Monitoring,switching,and stopping multiple sclerosis disease-modifying therapies[J].Continuum,2019,25(3):715.

[14]AMIN M,HERSH C M.Updates and advances in multiple sclerosis neurotherapeutics[J].Neurodegener Dis Manag,2023,13(1):47.

[15]韦石凤,赵志刚.多发性硬化症的药物治疗及药学监护[J].医药导报,2023,42(5):742.

[16]OLSSON T,BOSTER A,FERNANDEZ O,et al.Oral ponesimod in re lapsing-remitting multiple sclerosis:a randomised phaseⅡtrial[J].J Neurol Neurosurg Psychiatry,2014,85(11):1198.

[17]ANNIBALI V,MECHELLI R,ROMANO S,et al.IFN-β and multiple sclerosis:from etiology to therapy and back[J].Cytokine Growth Factor Rev,2015,26(2):221.

[18]ALEXANDRE X,PIA C M,MALTBY VICKI E,et al.Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis[J].Front Immunol,2023,14:1162796.

[19]TRABOULSEE A,LI D K B,CASCIONE M,et al.Effect of interferon beta-la subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year1[J].BMC Neurol,2018,18(1):1.

[20]张蔚蔚.干扰素β-1b治疗复发缓解型多发性硬化的疗效评价[J].中国医药指南,2018,16(3):69.

[21]COHAN S L, HENDIN B A,REDER A T, et al.Interferons and multiple sclerosis:lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a(avonex)[J].CNS Drugs,2021,35(7):743.

[22]PABLO A G,ISAAC H G,LUNDAHL C P N,et al.Soluble receptor isoform of IFN-beta(sIFNAR2)in multiple sclerosis patients and their association with the clinical response to IFN-beta treatment[J].Front Immunol,2021,12:778204.

[23]AHARONI R.The mechanism of action of glatiramer acetate in multiple sclerosis and beyond[J].Autoimmun Rev,2013,12(5):543.

[24]LEBRUN-FRENAY C,MOULIGNIER A,PIERROTDESEILLIGNY C,et al.Five-year outcome in the copaxone observatory:a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France[J].J Neurol,2019,266(4):888.

[25]KALA M,MIRAVALLE A,VOLLMER T.Recent insights into the mechanism of action of glatiramer acetate[J].J Neuroimmunol,2011,235(1-2):9.

[26]LEAL G,BRAMHAM C R,DUARTE C B.BDNF and hippocampal synaptic plasticity[M].Amsterdam:Elsevier,2017:153.

[27]CIPLEA A I,KURZEJA A,THIEL S,et al.Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis[J].Mult Scler Relat Disord,2023,75:104771.

[28]BAR-OR A,PACHNER A,MENGUY-VACHERON F,et al.Teriflunomide and its mechanism of action in multiple sclerosis[J].Drugs,2014,74(6):659.

[29]MILLER A E,XU X H,MACDONELL R,et al.Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis:a subgroup analysis of the phase 3 TOWER study[J].J Clin Neurosci,2019,59:229.

[30]MILLER A E,OLSSON T P,WOLINSKY J S,et al.Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis:results from the TOWER extension study[J].Mult Scler Relat Disord,2020,46:102438.

[31]VARYTE G,ARLAUSKIENE A, RAMASAUSKAITE D.Pregnancy and multiple sclerosis:an update[J].Curr Opin Obstet&Gynecol,2021,33:378.

[32]VUKUSIC S,COYLE P K,JURGENSEN S,et al.Pregnancy outcomes in patients with MS treated with teriflunomide:clinical study and postmarketing data(P4.361)[J].Neurology,2018,90(15 supplement):829.

[33]HENSON L J,AFSAR S,DAVENPORT L,et al.Pregnancy outcomes in patients treated with leflunomide,the parent compound of the multiple sclerosis drug teriflunomide[J].Reprod Toxicol,2020,95:45.

[34]SLOMSKI A.Teriflunomide reduced lesions in pediatric multiple sclerosis[J].JAMA,2022,327(4):314.

[35]CHITNIS T,BANWELL B,KAPPOS L,et al.Safety and efficacy of teriflunomide in paediatric multiple sclerosis(TERIKIDS):a multicentre,double-blind,phase 3,randomised,placebo-controlled trial[J].Lancet Neurol.2021,20(12):1001.

[36]YADAV S K,SOIN D,ITO K,et al.Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis[J].J Mol Med,2019,97(4):463.

[37]MAJKUTEWICZ I.Dimethyl fumarate:a review of preclinical efficacy in models of neurodegenerative diseases[J].Eur J Pharmacol,2022,926:175025.

[38]ALROUGHANI R,DAS R,PENNER N,et al.Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis(FOCUS)[J].Pediatr Neurol,2018,83:19.

[39]GOLD R,KAPPOS L,ARNOLD D L,et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis[J].N Engl J Med,2012,367(12):1098.

[40] Australian Prescriber.New drug:diroximel fumarate for multiple sclerosis[J].Anst Prescr,2022,45(5):180.

[41]JORDAN A L,YANG J,FISHER C J,et al.Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients[J].Mult Scler,2022,28(1):7.

[42]MARGONI M.PREZIOSA P,FILIPPI M,et al.Anti-CD20therapies for multiple sclerosis:current status and future perspectives[J].J Neurol,2022,269(3):13 16.

[43]SELLEBJERG F,BLINKENBERG M,SORENSEN P S.AntiCD20 monoclonal antibodies for relapsing and progressive multiple sclerosis[J].CNS Drugs,2020,34(3):269.

[44]LAMB Y N.Ocrelizumab:a review in multiple sclerosis[J].Drugs,2022,82(3):323.

[45]JUANATEY GARCíA A,BLANCO GARCíA L,TéLLEZ LARAN.Ocrelizumab:eficacia y seguridad en la esclerosis multiple[J].RevNeUrol.2018,66(12):423.

[46]PONTIERI L,BLINKENBERG M,BRAMOW S,et al.Ocrelizumab treatment in multiple sclerosis:a Danish populationbased cohort study[J].Eur J Neurol,2022,29(2):496.

[47]SLADOWSKA K,KAWALEC P,HOLKO P,et al.Comparative safety of high-efficacy disease-modifying therapies in relapsingremitting multiple sclerosis:a systematic review and network meta-analysis[J].Neurol Sci,2022,43(9):5479.

[48]PAPE K,ROLFES L,STEFFEN F,et al.Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis:a realworld propensity score-matched study[J].Ther Adv Neurol Disord,2022,15:17562864221142924.

[49]DOBSON R,ROG D,OVADIA C,et al.Anti-CD20 therapies in pregnancy and breast feeding:a review and ABN guidelines[J].Pract Neurol,2023,23(1):6.

[50]KATHARINA F,AGNES G,PETER A,et al.Multiple sclerosis,disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes:results from a population-based cohort study[J].Mult Scler Houndmills Basingstoke Engl,2023,29(6):1352458523 1161492.

[51]KANG C.BLAIR H A.Ofatumumab:a review in relapsing forms of multiple sclerosis[J].Drugs,2022,82(1):55.

[52]HAUSER S L.B AR-OR A,COHEN J A,et al.Ofatumumab versus teriflunomide in multiple sclerosis[J].N Engl J Med,2020,383(6):546.

[53]European Medicines Agency.Kesimpta[EB/OL].(2021-01-25)[2023-06-25].https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta.

[54]MILO R,OSHEROV M.Daclizumab and its use in multiple sclerosis treatment[J].Drugs Today,2017,53(1):7.

[55]CURTI E,TSANTES E, BALDI E,et al.The real-worldeffectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis.An Italian multicentre study[J].Mult Scler Relat Disord,2019,33:146.

[56]SAPONARO A C,TULLY T,MAILLART E,et al.Treatments of paediatric multiple sclerosis:efficacy and tolerance in a longitudinal follow-up study[J].Eur J Paediatr Neurol,2023,45:22.

[57]SAIDA T,KIRA J I,KISHIDA S,et al.Efficacy,safety,and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients:a double-blind,randomized controlled trial and openlabel pharmacokinetic study[J].Mult Scler Relat Disord,2017,11:25.

[58]CHAPPUIS M,ROUSSEAU C,BAJEUX E,et al.Discontinuation of second-versus first-line disease-modifying treatment in middleaged patients with multiple sclerosis[J].J Neurol,2023,270(1):413.

[59]HAVRDOVA E,ARNOLD D L,COHEN J A,et al.Alemtuzumab CARE-MS 15-year follow-up:durable efficacy in the absence of continuous MS therapy[J].Neurology,2017,89(11):1107.

[60]FRAU J,COGHE G,LOREFICE L,et al.Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis[J].J Neurol,2019,266(6):1405.

[61]POURNAJAF S,DARGAHI L,JAVAN M, et al.Molecular pharmacology and novel potential therapeutic applications of fingolimod[J].Front Pharmacol,2022,13:807639.

[62]GAUER L,BIGAUT K,BERGER,et al.A decade of fingolimod in multiple sclerosis:insights from a large real-world cohort study[J].Rev Neurol,2023,179(6):576.

[63]RUSSO M,GUARNERI C,MAZZON E,et al.Fingolimodassociated peripheral vascular adverse effects[J].Mayo Clin Proc,2015,90(10):1424.

[64]CHRISTINA K,CHRISTINA K.Fingolimod-associated macular edema:a case report of late onset[J].Eur J Ophthalmol,2021,32(4):1120672121999632.

[65]SZéPLAKI G,MERKELY B.Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis[J].Ideggyogyaszati Szemle,2012,65(11-12):369.

[66]MENDIBE BILBAO M,BOYERO DURáN S,BáRCENA LLONA J,et al.Multiple sclerosis:pregnancy and women's health issues[J].Neurol Engl Ed,2019,34(4):259.

[67]THOMAS K,PROSCHMANN U,ZIEMSSEN T.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis[J].Expert Opin Pharmacother,2017,18(15):1649.

[68]KAPPOS L,BAR-OR A,CREE B A C,et al.Siponimod versus placebo in secondary progressive multiple sclerosis(EXPAND):a double-blind,randomised,phase 3 study[J].Lancet,2018,391(10127):1263.

[69]KAPPOS L,LI D K B,STüVE O,et al.Safety and efficacy of siponimod(BAF312)in patients with relapsing-remitting multiple sclerosis:dose-blinded,randomized extension of the phase 2BOLD study[J].JAMA Neurol,2016,73(9):1089.

[70]DIMITRIOU N G,MEUTH S G,MARTINEZ-LAPISCINA E H,et al.Treatment of patients with multiple sclerosis transitioning between relapsing and progressive disease[J].CNS Drugs,2023,37(1):69.

[71]CREE B A,ARNOLD D L,FOX R J,et al.Long-term efficacyand safety of siponimod in patients with secondary progressive multiple sclerosis:analysis of EXPAND core and extension data up to>5 years[J].Mult Scler,2022,28(10):1591.

[72]SCOTT F L,CLEMONS B, BROOKS J,et al.Ozanimod(RPC 1063)is a potent sphingosine-1-phosphate receptor-1(S1P1)and receptor-5(S1P5)agonist with autoimmune disease-modifying activity[J].Br J Pharmacol,2016,173(11):1778.

[73]CREE B A,SELMAJ K W,STEINMAN L,et al.Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis:up to 5years of follow-up in the DAYBREAK open-label extension trial[J].Mult Scler,2022,28(12):1944.

[74]KANTOR D,PHAM T,PATTERSON-LOMBA O,et al.Cost per relapse avoided for ozanimod versus other selected diseasemodifying therapies for relapsing-remitting multiple sclerosis in the United States[J].Neurol Ther,2023,12(3):849.

[75]ALNAIF A,OILER I,D'SOUZA M.Ponesimod:an oral secondgeneration selective sphingosine 1-phosphate receptor modulator for the treatment of multiple sclerosis[J].Ann Pharmacother,2022,57:956.

[76]FREEDMAN M S,POZZILLI C,HAVRDOVA E K,et al.Longterm treatment with ponesimod in relapsing-remitting multiple sclerosis:results from randomized phase 2b core and extension studies[J].Neurology,2022,99(8):e762.

[77]KAPPOS L,FOX R J,BURCKLEN M,et al.Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study:a randomized clinical trial[J].JAMA Neurol,2021,78(5):558.

[78]JACOBS B M,AMMOSCATO F,GIOVANNONI G,et al.Cladribine:mechanisms and mysteries in multiple sclerosis[J].J Neurol Neurosurg Psychiatry,2018,89(12):1266.

[79]GIOVANNONI G,SOELBERG SORENSEN P,COOK S,et al.Safety and efficacy of cladribine tablets in patients with relapsingremitting multiple sclerosis:results from the randomized extension trial of the CLARITY study[J].Mult Scler,2018,24(12):1594.

[80]MOSER T,ZIEMSSEN T,SELLNER J.Real-world evidence for cladribine tablets in multiple sclerosis:further insights into efficacy and safety[J].Wien Med Wochenschr,2022,172(15-16):365.

[81]SPELMAN T,OZAKBAS S,ALROUGHANI R,et al.Comparative effectiveness of cladribine tablets versus other oral diseasemodifying treatments for multiple sclerosis:results from MSBase registry[J].Mult Scler,2023,29(2):221.

[82]COOK S,VERMERSCH P,COMI G,et al.Safety and tolerability of cladribine tablets in multiple sclerosis:the CLARITY(CLAdRIbine Tablets treating multiple sclerosis orallY)study[J].Mult Scler Houndmills Basingstoke Engl,2011,17(5):578.

[83]CHANVILLARD C,MILLWARD J M,LOZANO M,et al.Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis[J].PLoS One,2012,7(6):e39625.

[84]CALLEGARI I,DERFUSS T,GALLI E.Update on treatment in multiple sclerosis[J].La Presse Médicale,2021,50(2):104068.